EU-GMP Certification for Cannabis: How and Why Canadian Producers Get Certified

For Canadian licensed producers, EU-GMP certification has become the single most valuable key to the fastest growing medical cannabis market in the world. Europe now buys more Canadian cannabis than ever, and almost all of that demand sits behind one quality standard. If your facility cannot prove it meets European Union Good Manufacturing Practice, you cannot sell pharmaceutical grade cannabis in Germany, and you are locked out of the markets that pay the highest prices for flower and extracts.

This guide explains what EU-GMP certification for cannabis is, why it matters more in 2026 than ever before, and the practical steps a Canadian producer needs to take to earn it and keep it.

Executive Summary

EU-GMP certification confirms that a cannabis facility manufactures, tests and documents its products to the pharmaceutical standard set out in EudraLex Volume 4, the European Union's official Good Manufacturing Practice framework. For Canadian producers, certification is what unlocks legal medical exports to Europe. Cultivation must follow Good Agricultural and Collection Practice (GACP), processing and manufacturing must follow EU-GMP, and distribution must follow Good Distribution Practice (GDP).

The commercial stakes are high. In the first quarter of 2026, Germany imported 50,539 kilograms of medical cannabis flower, and Canada supplied 53 percent of that total, roughly 26,753 kilograms. Germany's CanG reform of April 2024 reclassified medical cannabis from a narcotic to an ordinary prescription medicine, which removed the biggest barrier to prescribing and sent demand sharply upward. EU-GMP is the gate every Canadian exporter must pass through to compete for that demand.

Certification is earned through inspection. A Canadian site is certified either by a European Union member state authority willing to inspect overseas, such as Germany's BfArM, Portugal's Infarmed or Denmark's DKMA, or by routing product through a licensed European processing site. On the Canadian side, Health Canada requires a separate export permit for every single shipment. The rest of this article walks through each of these pieces in plain language.

What Is EU-GMP Certification for Cannabis?

EU-GMP certification for cannabis is formal confirmation from a European regulatory authority that a facility produces cannabis to the European Union's pharmaceutical manufacturing standard. The standard itself is published in EudraLex Volume 4, and it is the same body of rules that governs conventional medicines made for the European market.

Good Manufacturing Practice is the minimum quality bar a pharmaceutical producer must meet in its manufacturing procedures. The European Medicines Agency (EMA) coordinates inspections and harmonizes GMP across the European Union. The principle is simple but demanding: any manufacturer of medicines intended for the European Union market, no matter where in the world it sits, must comply with GMP.

In practice, EU-GMP requires that products are of consistently high quality, are appropriate for their intended use, and meet the requirements of the relevant marketing authorization or clinical trial authorization. For cannabis, the heart of certification is proving that your process after harvest is validated and repeatable, so that every batch comes out the same way, with the same identity, purity and potency.

Canadian producers often ask how this differs from the Good Production Practices (GPP) they already follow under the Cannabis Regulations. GPP keeps Canadian cannabis safe for the domestic market, but it is not a pharmaceutical standard and it is not recognized in Europe. EU-GMP is stricter on documentation, validation, quality oversight and the role of the Qualified Person. Our breakdown of EU-GMP versus GPP explains where the two standards diverge and why the gap matters.

Why EU-GMP Certification Matters in 2026

EU-GMP matters because it is the difference between reaching Europe and being shut out of it. Europe rewards certified producers with higher prices and steady demand, and 2026 has made that reward larger than at any point since legalization.

The numbers tell the story. Germany imported 50,539 kilograms of medical cannabis flower in the first quarter of 2026, an increase of about 34 percent compared with the same period a year earlier. Canada was the largest single supplier, accounting for 53 percent of imports. Across all of 2025, Canada and Portugal together supplied roughly 74 percent of what Germany brought in. For a Canadian producer with spare capacity, that is a market worth building a quality system around.

The reason demand jumped is regulatory, not just commercial. Germany's Cannabis Act reform, known as CanG, took effect on 1 April 2024 and moved medical cannabis out of the narcotics law (the BtMG) and into the ordinary medicines law (the AMG). Before that change, cannabis was treated as a Schedule I narcotic even when a doctor prescribed it, which buried prescribers in paperwork. After CanG, any licensed physician in Germany can prescribe cannabis based medicinal products without the old narcotics restrictions. More prescriptions mean more imported flower, and more imported flower means more EU-GMP certified supply is needed.

For Canadian leadership teams, the takeaway is direct. EU-GMP certification is no longer a niche project for a handful of large producers. It is a strategic decision about whether your business participates in the most valuable cannabis export market available to Canada.

GACP, GMP and GDP: The Three Standards That Work Together

Three quality standards govern the journey of medical cannabis from a seed in Canada to a patient in Europe. Each covers a different stage, and a compliant export depends on all three.

Good Agricultural and Collection Practice (GACP)

GACP covers the growing stage. The EMA requires that herbal products derived from plant material follow Good Agricultural and Collection Practice, set out in the EMA guideline on GACP for starting materials of herbal origin. The goal is consistent, acceptable quality in the raw plant material before it ever reaches a processing room. GACP reaches across cultivation, harvesting and primary processing, and it demands proper quality assurance over how material is grown, gathered, dried and handled.

For cannabis, GACP is the foundation. To receive EU-GMP certification for exporting medical cannabis to Europe, a producer must first demonstrate GACP compliance for the cultivation side of the operation.

Good Manufacturing Practice (GMP)

GMP covers manufacturing and processing. Once the plant material is harvested, EU-GMP governs how it is dried, processed, tested, packaged and released. This is where validation, batch records, environmental controls, deviation management and the Qualified Person come into play. GMP is the standard most people mean when they say EU-GMP certification, and it is the most documentation heavy of the three.

Good Distribution Practice (GDP)

GDP covers storage and transport. Good Distribution Practice describes the minimum standards a wholesale distributor must meet so that the quality and integrity of medicines is maintained across the supply chain. Compliance with GDP ensures that medicines are properly authorized under European Union law, are stored in the right conditions at all times including during transport, are protected from contamination, move with adequate stock turnover, and reach the correct recipient within a reasonable time. Distributors must also keep a tracing system to locate faulty products and run an effective recall procedure.

Anyone carrying out wholesale distribution of medicinal products in the European Economic Area must hold a wholesale distribution authorization issued by the national competent authority of the member state where they operate, and that authority inspects them.

The table below summarizes how the three standards divide the work.

Standard	Stage it covers	Who issues or oversees it	What it proves
GACP	Cultivation, harvest, primary processing	EMA guideline, assessed during certification	Raw plant material is grown and handled to consistent quality
EU-GMP	Processing, testing, packaging, release	EU member state authority (for example BfArM)	Manufacturing is validated, documented and repeatable
GDP	Storage, wholesale, transport	National competent authority via distribution authorization	Product integrity is maintained through the supply chain

How Canadian Producers Get EU-GMP Certified

Canadian producers reach EU-GMP certification through one of two routes, and both end in a successful inspection. There is no certificate without an audit by, or on behalf of, a European authority.

The first route is direct certification by a European Union member state authority that is willing to travel and inspect a facility outside Europe. Germany's BfArM, Portugal's Infarmed and Denmark's DKMA have all conducted international EU-GMP inspections of third country sites in Canada and elsewhere. The second route is to ship product to a licensed European based site that holds its own EU-GMP authorization and carries out further processing, testing and release inside Europe.

Whichever route you choose, the European importer must hold a Manufacturing and Import Authorisation (MIA) for the site where physical importation takes place. Every batch entering the European Union must then be certified by a Qualified Person (QP) based in Europe, and that certification happens only after the product has physically arrived and cleared customs. Because Canada and the European Union do not have a mutual recognition agreement for cannabis, every imported batch must also be retested by a European based laboratory holding valid GMP certification.

Germany adds its own layer. Importing cannabis flower from a third country into Germany requires an import permit under Section 72 of the German medicines law (the AMG), proof that cultivation followed GACP and that production and testing followed EU-GMP, and a permit under Section 4 of the Medical Cannabis Act (MedCanG) issued by BfArM.

The path below shows the typical sequence for a Canadian producer pursuing direct certification.

Step	What happens	Typical owner
1. Gap assessment	Compare current GPP operation against EU-GMP and GACP requirements	Quality and regulatory team or consultant
2. Remediation	Build or upgrade the quality system, SOPs, validation and facility controls	Quality Assurance
3. Documentation	Complete the Site Master File, validation master plan and batch records	Quality Assurance
4. Mock audit	Run an internal or third party inspection readiness audit and close gaps	Auditor or consultant
5. Application and inspection	Apply to the chosen EU authority and host the on-site inspection	Regulatory Affairs
6. CAPA and certification	Respond to inspection findings, close them, and receive the EU-GMP certificate	Quality and Regulatory
7. Ongoing compliance	Maintain the system, manage change and prepare for periodic reinspection	Quality Assurance

A realistic timeline from first gap assessment to certificate is often 12 to 24 months, depending on the starting condition of the facility and quality system. The single biggest variable is documentation maturity, which is why a structured gap assessment at the start saves both time and money.

Other Regulatory Requirements on the Canadian Side

European rules are only half the picture. A Canadian producer exporting medical cannabis to Europe must also satisfy Health Canada under the Cannabis Act and the Cannabis Regulations.

Only parties licensed under the Cannabis Regulations may import or export cannabis, and they may do so only for medical or scientific purposes. A permit is required for each individual shipment, so the export permit process repeats every time product leaves the country. Health Canada's general policy is to issue export permits only in limited circumstances, such as exporting cannabis products to a country that has a legal regime for access to cannabis for medical purposes.

When assessing an export permit application, Health Canada considers whether the request is consistent with the Cannabis Act and its regulations, whether the cannabis will be used solely for medical or scientific purposes, whether the destination country has issued its own import permit, and whether there are risks to public health or safety. Exporters should plan for this permit cycle on every shipment and build it into their logistics, not treat it as a one time approval. Our import and export compliance support helps producers manage these permits shipment by shipment.

EU-GMP Cannabis Compliance Checklist

Use this checklist as a high level readiness scan before you invite an inspector. It is not a substitute for a full gap assessment, but it covers the areas that most often decide whether a site passes.

A documented quality management system with a current Site Master File
GACP controls in place across cultivation, harvest and drying
A validation master plan covering process, cleaning, equipment and analytical methods
Qualified and validated computerized systems with data integrity controls
Batch manufacturing and packaging records that are complete and contemporaneous
A deviation, CAPA and change control system that is actually used, not just written
Environmental monitoring and controlled areas appropriate to the products made
A stability program supporting the assigned shelf life
A named relationship with a European importer holding an MIA and access to a Qualified Person
A plan for batch retesting at a European based GMP laboratory
Supplier and vendor qualification records
Trained staff with documented competency and clear roles
A Health Canada export permit process mapped for every shipment
Internal audit and management review running on a defined schedule

Common Mistakes Canadian Producers Make

Most failed or delayed certifications trace back to a short list of avoidable errors. Knowing them in advance is the cheapest insurance you can buy.

The most common mistake is treating EU-GMP as a paperwork exercise layered on top of GPP. EU-GMP is a different operating philosophy, and bolting a few new forms onto an existing GPP system almost always leaves gaps that an inspector finds quickly. The second mistake is weak documentation. Records that are filled in after the fact, missing signatures or incomplete batch records are among the fastest ways to fail an inspection, because they undermine trust in everything else.

A third frequent error is underestimating validation. Producers often have equipment and processes running well in practice but cannot prove, on paper, that those processes are validated and repeatable. A fourth is forgetting the European importer and Qualified Person early enough. Certification of your site means little if there is no European partner holding an MIA to import the product and no Qualified Person to release each batch. A fifth is ignoring data integrity in computerized systems, an area European inspectors scrutinize closely. Finally, many producers neglect the Health Canada export permit cycle and discover too late that every shipment needs its own approval.

How MFLRC Can Help

EU-GMP certification is a large, technical project, and it is exactly the kind of work MF License and Regulatory Consultants (MFLRC) was built to lead. With more than twenty years of quality assurance, quality control and regulatory affairs experience across pharmaceutical, cannabis and adjacent sectors, we guide Canadian producers through certification from first assessment to final certificate.

Our support across the EU-GMP journey includes:

Gap assessments that measure your current operation against EU-GMP and GACP and produce a clear, prioritized remediation plan
SOP and quality system development that builds the documented, defensible quality management system European inspectors expect
Pharmaceutical validation services covering process, equipment, cleaning, analytical method and computerized system validation
Audit services, including mock inspections and inspection readiness assessments, so you walk into the real audit prepared
Quality Assurance Person and QAP support to strengthen quality oversight and batch release discipline
Regulatory affairs, licensing and import and export support, including Health Canada export permits and coordination with your European importer

We work the way regulators do, with structured, evidence backed deliverables rather than generic checklists. The result is a certification project that holds up under inspection and a quality system you can actually run afterward.

Need help with EU-GMP certification or export compliance? Contact MFLRC for expert guidance tailored to your facility.

Book a Consultation

Conclusion

EU-GMP certification is the credential that turns a Canadian cannabis licence into a passport for the European medical market. The standard is demanding because the prize is large: Europe pays premium prices, Germany's demand is climbing after CanG, and Canada already supplies more than half of that country's imports. Certification rests on three standards working together, GACP for cultivation, EU-GMP for manufacturing and GDP for distribution, and it is earned through inspection by a European authority, supported on the Canadian side by Health Canada export permits.

Producers that start with an honest gap assessment, build a genuine quality system rather than a paper one, and line up their European importer early are the ones that certify on time and stay certified. With the right guidance, EU-GMP certification is an achievable, repeatable, and highly profitable step. To explore more on Canadian cannabis compliance, browse the MFLRC cannabis and hemp resources or our full article library.

Frequently Asked Questions

What is EU-GMP certification for cannabis?

EU-GMP certification for cannabis is confirmation from a European regulatory authority that a facility manufactures cannabis to the European Union's pharmaceutical standard set out in EudraLex Volume 4. It is required to sell pharmaceutical grade medical cannabis anywhere in the European Union.

Why do Canadian producers need EU-GMP certification?

Without EU-GMP certification, a Canadian producer cannot legally supply medical cannabis to European markets such as Germany. Certification unlocks the highest value export market available to Canada, where Canada already supplies more than half of Germany's imports.

What is the difference between GPP and EU-GMP?

Good Production Practices (GPP) is the Canadian standard under the Cannabis Regulations that keeps cannabis safe for the domestic market. EU-GMP is a stricter pharmaceutical standard with deeper requirements for validation, documentation, quality oversight and Qualified Person batch release, and it is the one Europe recognizes.

How long does EU-GMP certification take?

The timeline depends on the starting condition of the facility and quality system, but a realistic range from first gap assessment to certificate is often 12 to 24 months. Documentation and validation maturity are usually the biggest factors.

Do I need EU-GMP certification to export cannabis to Germany?

Yes. Germany requires proof that cultivation followed GACP and that production and testing followed EU-GMP, plus import permits under the German medicines law and the Medical Cannabis Act issued by BfArM. The product must also be released by a European Qualified Person and retested in Europe.

Who inspects Canadian facilities for EU-GMP?

A European Union member state authority willing to inspect overseas does, with Germany's BfArM, Portugal's Infarmed and Denmark's DKMA among those that have conducted international EU-GMP inspections. Alternatively, product can be processed and released through a licensed European site.

Does Health Canada still play a role in exports?

Yes. Only parties licensed under the Cannabis Regulations may export cannabis, and only for medical or scientific purposes. Health Canada requires a separate export permit for every shipment, issued only in limited circumstances.